Processa Pharmaceuticals, Inc. (PCSA) Stock Price & Analysis

Processa Pharmaceuticals, Inc. (PCSA) rose 0.49% to USD 2.06 as of September 8, 2026 at 12:43 UTC, according to Nexqual real-time market data.

PCSA last closed at USD 2.06; the session ranged USD 2.01–2.07 on volume of 12,344 shares. Market capitalization is —, with a 52-week range of USD 1.67–14.25 (NCM). Source: Nexqual, September 8, 2026 at 12:43 UTC.

Key Statistics (as of September 8, 2026 at 12:43 UTC)

Technical Analysis (PCSA)

Nexqual's technical model rates PCSA "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 12:43 UTC.

From Processa Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)

Key Strengths & Strategy (as disclosed to the SEC)

• Capecitabine Market Size - By Indication (Breast, Colorectal, Gastric, Pancreatic), By Synthesis Type (Chemical Based API, Biological API, Highly Potent API, Mode, Global Forecast 2023- 2032 .
• North America Capecitabine Market Research Report - Segmented By Application, Drug Formulation & Country (U.S, Canada & Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2024 to 2032) .
• We then efficiently develop our pipeline of Next Generation Cancer therapies utilizing our proprietary Regulatory Science Approach, which we believe will further increase the likelihood of regulatory approval.
• We believe our approach will extend survival and improve quality of life for many patients fighting cancer.

Partnerships

• We are also required to split any sales milestone payments or royalties we receive with Aposense based on any sub-license agreement we may enter.   License Agreement with Yuhan Corporation   On August 19, 2020, we entered into a License Agreement with Yuhan Corporation ("Yuhan License Agreement"), pursuant to which we acquired an exclusive license to develop, manufacture and commercialize PCS12852 globally, excluding South Korea.
• Sian Bigora, developed trade secrets and know-how developed from the regulatory science research initially developed in collaboration with FDA and later refined by Drs.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:43 UTC. This page is informational and not investment advice.